1. Pink Sheet
  2. >>Archive

Reimportation Revived? Or an Issue about to Expire?

 
• By Cole Werble

Support for reimportation of lower-priced drugs from outside the US has been a rallying point for Democratic critics of the drug industry for almost a decade. But there are signs that some influential Democrats now view it as a distraction from the real target-cutting drug costs here.

Cole Werble

Pharma is still fighting the reimportation battle, but there are signs that at long last the industry’s political nemesis may be ready to perish. The thing is, if reimportation finally...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

EU To Track Decentralized Clinical Trials In CTIS To Support Innovation

 
• By Vibha Sharma

Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.

Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A

 
• By Neena Brizmohun

Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.

Autolus’s Aucatzyl And GSK’s Blenrep Among 10 New Drugs To Get EMA Nod

 
• By Vibha Sharma

The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.